All In Biotech

Drug Trial Radar · NCT03525886

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia

Last checked: Nov 19, 2026Latest source record: May 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Apr 10, 2018

Primary completion

Apr 7, 2020

Study completion Apr 7, 2020

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
May 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 in up to 30 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). The study will include a sequential-cohort design with four NBI-74788 dosing regimens, with each regimen administered for 14 days.

Conditions

  • CAH - Congenital Adrenal Hyperplasia

Interventions

  • NBI-74788Drug

    Capsule, administered daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window AveragesTime frame: Baseline and Day 14

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Aurora, Colorado

  • Neurocrine Clinical Site

    Indianapolis, Indiana

  • Neurocrine Clinical Site

    Ann Arbor, Michigan

  • Neurocrine Clinical Site

    Minneapolis, Minnesota

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania

  • Neurocrine Clinical Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.